Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

PI3K expression predicts overall survival in lung adenocarcinoma.

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

The Expression and Prognostic Significance of PIK3CB in Lung Adenocarcinoma

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

STAT3/p-STAT3 Expression is Correlated with Clinicopathological Characteristics and Prognosis in Non-Small Cell Lung Cancer.

Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis

High expression of PIK3CB is an independent prognostic predictor for gastric adenocarcinoma

Clinical Significance of Pik3ca and Survivin in Primary Adenosquamous Lung Carcinoma

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Protein Expression of Programmed Death 1 Ligand 1 and Ligand 2 Independently Predict Poor Prognosis in Surgically Resected Lung Adenocarcinoma

Correlation Between Pgsk-3Β Expression and Prognosis in Non-Small Cell Lung Cancer

Prognostic significance of signal transducers and activators of transcription 3 and p-signal transducers and activators of transcription 3 expression in patients with non-small cell lung cancer

Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma

Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.

Peptidyl-prolyl Isomerase F As a Prognostic Biomarker Associated with Immune Infiltrates and Mitophagy in Lung Adenocarcinoma

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

PIG3 Promotes NSCLC Cell Mitotic Progression and is Associated with Poor Prognosis of NSCLC Patients

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.